down arrow

Daxor Corp.

  • Market Cap: N/A
  • Industry: Capital Markets
  • ISIN: US2394671034
USD
12.85
-0.25 (-1.91%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

12.7013.02

52 Week

6.5514.15
Valuation
Technical
Day's Volume

CASH

1.53 k

Shareholding (Dec 2024)

FII

0.06%

Held by 1 FIIs

DII

98.93%

Held by 1 DIIs

Promoter

0.00%

How big is Daxor Corp.?

22-Jun-2025

As of Jun 18, Daxor Corp. has a market capitalization of 43.53 million, with net sales of 1.45 million and a net profit of -7.18 million over the last four quarters. The company has shareholder's funds of 35.79 million and total assets of 36.63 million as of Dec 24.

Market Cap: As of Jun 18, Daxor Corp. has a market capitalization of 43.53 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Daxor Corp. reported net sales of 1.45 million and a net profit of -7.18 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company has shareholder's funds amounting to 35.79 million and total assets of 36.63 million.

Read More

What does Daxor Corp. do?

22-Jun-2025

Daxor Corporation is an investment company specializing in medical instrumentation and biotechnology, primarily focused on developing the Blood Volume Analyzer (BVA) -100. As of December 2011, it reported net sales of $0 million and a net profit of -$1 million, with a market cap of $43.53 million.

Overview: <BR>Daxor Corporation is an investment company engaged in medical instrumentation and biotechnology, focusing on the development of the Blood Volume Analyzer (BVA) -100 within the Capital Markets industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Dec 2011) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Dec 2011) <BR>Market-cap: USD 43.53 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 32.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.03 <BR>Return on Equity: 3.68% <BR>Price to Book: 1.22<BR><BR>Contact Details: <BR>Address: 350 5th Ave Ste 4740, NEW YORK NY: 10118-0002 <BR>Tel: ['1 212 3308500', '1 212 3308512'] <BR>Fax: 1 212 2440806 <BR>Website: http://www.daxor.com/

Read More

Who are in the management team of Daxor Corp.?

22-Jun-2025

As of March 2022, the management team of Daxor Corp. includes Mr. Michael Feldschuh (Chairman, President, CEO), Mr. Jonathan Feldschuh (Chief Scientific Officer), and several directors: Henry Cremisi, Edward Feuer, Joy Goudie, James Lombard, and Robert Willens.

As of March 2022, the management team of Daxor Corp. includes the following individuals:<BR><BR>- Mr. Michael Feldschuh: Chairman of the Board, President, Chief Executive Officer<BR>- Mr. Jonathan Feldschuh: Chief Scientific Officer, Director<BR>- Henry Cremisi: Director<BR>- Edward Feuer: Director<BR>- Joy Goudie: Independent Director<BR>- Mr. James Lombard: Independent Director<BR>- Mr. Robert Willens: Independent Director

Read More

Is Daxor Corp. technically bullish or bearish?

20-Sep-2025

As of July 7, 2025, Daxor Corp. has a bullish technical trend supported by positive MACD indicators and daily moving averages, despite mixed signals from Bollinger Bands and no clear trends in RSI or OBV.

As of 7 July 2025, the technical trend for Daxor Corp. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, supporting a positive outlook. The daily moving averages also indicate a bullish stance. While the Bollinger Bands show a mildly bullish trend on the weekly chart and bullish on the monthly, the KST is bullish weekly and mildly bullish monthly. The Dow Theory indicates a mildly bullish stance on the monthly timeframe, but there is no trend on the weekly. The RSI shows no signal for both weekly and monthly periods, and the OBV has no trend in either timeframe. There is no available return data for comparison with the S&P 500. Overall, the current technical stance is bullish with moderate strength.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Capital Markets

stock-summary
Market cap

USD 55 Million ()

stock-summary
P/E

32.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.03

stock-summary
Return on Equity

3.68%

stock-summary
Price to Book

1.54

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Dec 2011)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
20.88%
0%
20.88%
6 Months
48.9%
0%
48.9%
1 Year
36.12%
0%
36.12%
2 Years
63.69%
0%
63.69%
3 Years
34.0%
0%
34.0%
4 Years
18.54%
0%
18.54%
5 Years
1.14%
0%
1.14%

Daxor Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Daxor Corp. technically bullish or bearish?

As of 7 July 2025, the technical trend for Daxor Corp. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, supporting a positive outlook. The daily moving averages also indicate a bullish stance. While the Bollinger Bands show a mildly bullish trend on the weekly chart and bullish on the monthly, the KST is bullish weekly and mildly bullish monthly. The Dow Theory indicates a mildly bullish stance on the monthly timeframe, but there is no trend on the weekly. The RSI shows no signal for both weekly and monthly periods, and the OBV has no trend in either timeframe. There is no available return data for comparison with the S&P 500. Overall, the current technical stance is bullish with moderate strength....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-0.54%
EBIT Growth (5y)
0
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.07
Tax Ratio
61.87%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
2.20%
ROCE (avg)
0
ROE (avg)
17.94%
Valuation key factors
Factor
Value
P/E Ratio
32
Industry P/E
Price to Book Value
1.19
EV to EBIT
NA
EV to EBITDA
42.66
EV to Capital Employed
1.19
EV to Sales
29.50
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
ROE (Latest)
3.68%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 1 Schemes (1.01%)

Foreign Institutions

Held by 1 Foreign Institutions (0.06%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Daxor Corp."
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.29% vs 8,750.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 66.67% vs -94.23% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "-0.10",
          "val2": "34.60",
          "chgp": "-100.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.60",
          "val2": "0.30",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.50",
          "val2": "0.30",
          "chgp": "66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "9.50%",
          "chgp": "-0.95%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
-0.10
34.60
-100.29%
Operating Profit (PBDIT) excl Other Income
0.60
0.30
100.00%
Interest
0.10
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
0.50
0.30
66.67%
Operating Profit Margin (Excl OI)
0.00%
9.50%
-0.95%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.29% vs 8,750.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 66.67% vs -94.23% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Daxor Corp. stock-summary
stock-summary
Daxor Corp.
Capital Markets
Daxor Corporation is an investment company with medical instrumentation and biotechnology operations. The Company focuses on the development of the Blood Volume Analyzer (BVA) -100, an instrument that rapidly and accurately measures human blood volume. The Company’s instrument is used in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.The Company also owns the Daxor Oak Ridge Operations (DORO) facility in Oak Ridge, Tennessee. The semi-automated BVA provides blood volume measurements in human body for diagnosis and treatment in a range of medical and surgical conditions.
Company Coordinates stock-summary
Company Details
350 5th Ave Ste 4740 , NEW YORK NY : 10118-0002
stock-summary
Tel: 1 212 33085001 212 3308512
stock-summary
http://www.daxor.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."